Trial reportHaematologica2019
Six months
Trial report in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Duration of primary/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis.Blood advances · 2025Pooled it
- Antithrombotic therapy for secondary prevention of unprovoked venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.Annals of medicine · 2022Pooled it
- Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2019Pooled it
- Practice patterns of pulmonologists regarding extended anticoagulation therapy after pulmonary embolism.BMC pulmonary medicine · 2026Article
- The incidence of early recurrent venous thromboembolism: a systematic review and meta-analysis.Research and practice in thrombosis and haemostasis · 2026Article
- Effects on mortality of extended versus short-term anticoagulation in venous thromboembolism: a systematic review and meta-analysis of randomized trials.Research and practice in thrombosis and haemostasis · 2025Article
- Clinical and Safety Outcomes Associated with Extended Treatment of Venous Thromboembolism: A Network Meta-Analysis.Journal of cardiovascular development and disease · 2022Review
- Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation.Journal of clinical medicine · 2022Review
- Current Trends in the Duration of Anticoagulant Therapy for Venous Thromboembolism: A Systematic Review.Cureus · 2021Review
- Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China.Frontiers in pharmacology · 2021Article
- Duration of anticoagulant treatment for unprovoked deep-vein thrombosis - is prolonged long enough?Haematologica · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal duration of anticoagulation after a first episode of unprovoked deep-vein thrombosis is uncertain. We aimed to assess the benefits and risks of an additional 18 months of treatment with warfarin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.